Literature DB >> 27622214

Technological advances in precision medicine and drug development.

Elaine Maggi1, Nicole E Patterson1, Cristina Montagna2.   

Abstract

New technologies are rapidly becoming available to expand the arsenal of tools accessible for precision medicine and to support the development of new therapeutics. Advances in liquid biopsies, which analyze cells, DNA, RNA, proteins, or vesicles isolated from the blood, have gained particular interest for their uses in acquiring information reflecting the biology of tumors and metastatic tissues. Through advancements in DNA sequencing that have merged unprecedented accuracy with affordable cost, personalized treatments based on genetic variations are becoming a real possibility. Extraordinary progress has been achieved in the development of biological therapies aimed to even further advance personalized treatments. We provide a summary of current and future applications of blood based liquid biopsies and how new technologies are utilized for the development of biological therapeutic treatments. We discuss current and future sequencing methods with an emphasis on how technological advances will support the progress in the field of precision medicine.

Entities:  

Keywords:  DNA methylation; biomarkers; cell free DNA; circulating tumor cells; diagnostic; drug development; extracellular vesicles; immunotherapy; precision medicine; target sequencing

Year:  2016        PMID: 27622214      PMCID: PMC5017245          DOI: 10.1080/23808993.2016.1176527

Source DB:  PubMed          Journal:  Expert Rev Precis Med Drug Dev        ISSN: 2380-8993


  138 in total

Review 1.  Gene silencing as a threat to the success of gene therapy.

Authors:  T H Bestor
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

Review 2.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

3.  Cell-free DNA analysis for trisomy risk assessment in first-trimester twin pregnancies.

Authors:  Maria del Mar Gil; Maria Soledad Quezada; Barbara Bregant; Argyro Syngelaki; Kypros H Nicolaides
Journal:  Fetal Diagn Ther       Date:  2013-11-15       Impact factor: 2.587

Review 4.  Extracellular vesicles: biology and emerging therapeutic opportunities.

Authors:  Samir EL Andaloussi; Imre Mäger; Xandra O Breakefield; Matthew J A Wood
Journal:  Nat Rev Drug Discov       Date:  2013-04-15       Impact factor: 84.694

5.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

6.  A microfluidic device for label-free, physical capture of circulating tumor cell clusters.

Authors:  A Fatih Sarioglu; Nicola Aceto; Nikola Kojic; Maria C Donaldson; Mahnaz Zeinali; Bashar Hamza; Amanda Engstrom; Huili Zhu; Tilak K Sundaresan; David T Miyamoto; Xi Luo; Aditya Bardia; Ben S Wittner; Sridhar Ramaswamy; Toshi Shioda; David T Ting; Shannon L Stott; Ravi Kapur; Shyamala Maheswaran; Daniel A Haber; Mehmet Toner
Journal:  Nat Methods       Date:  2015-05-18       Impact factor: 28.547

Review 7.  Adoptive T-cell therapy: adverse events and safety switches.

Authors:  Siok-Keen Tey
Journal:  Clin Transl Immunology       Date:  2014-06-20

8.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.

Authors:  Robert C Green; Jonathan S Berg; Wayne W Grody; Sarah S Kalia; Bruce R Korf; Christa L Martin; Amy L McGuire; Robert L Nussbaum; Julianne M O'Daniel; Kelly E Ormond; Heidi L Rehm; Michael S Watson; Marc S Williams; Leslie G Biesecker
Journal:  Genet Med       Date:  2013-06-20       Impact factor: 8.822

9.  Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.

Authors:  Nicola Aceto; Aditya Bardia; David T Miyamoto; Maria C Donaldson; Ben S Wittner; Joel A Spencer; Min Yu; Adam Pely; Amanda Engstrom; Huili Zhu; Brian W Brannigan; Ravi Kapur; Shannon L Stott; Toshi Shioda; Sridhar Ramaswamy; David T Ting; Charles P Lin; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran
Journal:  Cell       Date:  2014-08-28       Impact factor: 41.582

10.  Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.

Authors:  Johan Skog; Tom Würdinger; Sjoerd van Rijn; Dimphna H Meijer; Laura Gainche; Miguel Sena-Esteves; William T Curry; Bob S Carter; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Cell Biol       Date:  2008-11-16       Impact factor: 28.824

View more
  3 in total

1.  Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variants.

Authors:  Eirwen M Miller; Nicole E Patterson; Jenna Marcus Zechmeister; Michal Bejerano-Sagie; Maria Delio; Kunjan Patel; Nivedita Ravi; Wilber Quispe-Tintaya; Alexander Maslov; Nichelle Simmons; Maria Castaldi; Jan Vijg; Rouzan G Karabakhtsian; John M Greally; Dennis Y S Kuo; Cristina Montagna
Journal:  Oncotarget       Date:  2017-10-26

Review 2.  Application of Radiomics for Personalized Treatment of Cancer Patients.

Authors:  Yiming Meng; Jing Sun; Na Qu; Guirong Zhang; Tao Yu; Haozhe Piao
Journal:  Cancer Manag Res       Date:  2019-12-30       Impact factor: 3.989

3.  Development of a Method to Implement Whole-Genome Bisulfite Sequencing of cfDNA from Cancer Patients and a Mouse Tumor Model.

Authors:  Elaine C Maggi; Silvia Gravina; Haiying Cheng; Bilal Piperdi; Ziqiang Yuan; Xiao Dong; Steven K Libutti; Jan Vijg; Cristina Montagna
Journal:  Front Genet       Date:  2018-01-23       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.